$242.8 B

PFE Mkt cap, 16-Aug-2018

$26.4 B

Pfizer Revenue Q2, 2019
Pfizer Gross profit (Q2, 2019)20.9 B
Pfizer Gross profit margin (Q2, 2019), %79.2%
Pfizer Net income (Q2, 2019)7.4 B
Pfizer Cash, 01-Jul-20182.7 B
Pfizer EV269 B

Pfizer Revenue

Pfizer revenue was $52.82 b in FY, 2016 which is a 8.1% year over year increase from the previous period.

Embed Graph

Pfizer Revenue Breakdown

Embed Graph

Pfizer revenue breakdown by business segment: 18.6% from GIP, 17.0% from VOC, 35.6% from Innovative Products and 28.7% from Established Products GEP

Pfizer Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

51.6 b49.6 b48.9 b52.8 b

Revenue growth, %

(4%)(2%)8%

Cost of goods sold

9.6 b9.6 b9.6 b12.3 b

Gross profit

42 b40 b39.2 b40.5 b

Gross profit Margin, %

81%81%80%77%

Sales and marketing expense

14.4 b14.1 b14.8 b14.8 b

R&D expense

6.7 b8.4 b7.7 b7.9 b

Operating expense total

21 b22.5 b22.5 b22.7 b

EBIT

11.4 b9.1 b7 b7.2 b

EBIT margin, %

22%18%14%14%

Pre tax profit

15.7 b12.2 b9 b8.4 b

Income tax expense

4.3 b3.1 b2 b1.1 b

Net Income

22.1 b9.2 b7 b7.2 b

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q2, 2017Q1, 2019Q2, 2019

Revenue

12.6 b11.4 b12.8 b12.4 b10.9 b11.9 b12.1 b12.9 b12.9 b26.4 b

Cost of goods sold

2.3 b2 b2.5 b2.4 b1.8 b2.6 b5.5 b

Gross profit

10.4 b9.3 b10.3 b10 b9 b10.3 b20.9 b

Gross profit Margin, %

82%82%81%81%83%80%79%

R&D expense

1.6 b1.6 b1.8 b1.8 b1.9 b1.7 b3.5 b

General and administrative expense

3.4 b3 b3.5 b3.6 b3.1 b3.4 b7 b

Operating expense total

5 b4.7 b5.3 b5.4 b5 b5.2 b10.5 b

Depreciation and amortization

1.2 b2.4 b

Pre tax profit

3.6 b2.8 b4 b3.6 b3.1 b2.4 b4.1 b8.7 b

Income tax expense

582 m1.1 b911 m706 m905 m567 m284 m535 m375 m556 m1.2 b

Net Income

2.6 b2.3 b2.9 b2.7 b2.4 b2.6 b2.1 b1.3 b3 b2 b3.6 b7.4 b

Pfizer Balance Sheet

Annual

usdY, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.2 b10.1 b2.2 b3.3 b3.6 b

Inventories

6.2 b5.7 b

Current Assets

56.2 b57.7 b43.8 b38.9 b

PP&E

12.4 b11.8 b

Goodwill

42.5 b42.1 b48.2 b54.4 b

Total Assets

172.1 b169.3 b167.5 b171.6 b

Accounts Payable

3.2 b3.4 b3.6 b4.5 b

Dividends Payable

1.7 b1.7 b1.9 b1.9 b

Short-term debt

Current Liabilities

23.4 b21.6 b29.4 b31.1 b

Long-term debt

30.5 b31.5 b28.8 b

Total Debt

30.5 b31.5 b28.8 b

Common Stock

461 m

Preferred Stock

24 m

Additional Paid-in Capital

77.3 b79 b81 b82.7 b

Retained Earnings

69.7 b72.2 b72 b71.8 b

Total Equity

76.6 b71.6 b

Debt to Equity Ratio

0.4 x0.4 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x

Financial Leverage

2.2 x2.4 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q2, 2017Q1, 2019Q2, 2019

Cash

2.1 b2.9 b3.4 b2.4 b3.6 b3.7 b3.1 b2.3 b2.7 b

Inventories

6.5 b6.1 b6.2 b6.4 b5.8 b5.8 b7.6 b7.6 b8.1 b8.1 b

Current Assets

59.5 b57.8 b58.3 b57 b49.4 b51.7 b45 b38.5 b41.3 b43.8 b35.9 b36.4 b34.8 b37.3 b

PP&E

12.4 b12.3 b12.2 b12 b11.5 b11.4 b13.7 b

Goodwill

42.4 b42.5 b42.7 b42.7 b41.9 b41.6 b47.2 b56.3 b48.6 b50.6 b54.7 b55 b56.4 b55.8 b

Total Assets

176 b172 b173 b171 b161 b161 b171 b178 b163 b171 b169 b169 b164.6 b165 b

Accounts Payable

2.3 b2.5 b3 b3 b2.7 b2.9 b3.3 b3.5 b3.1 b3.3 b3.4 b3.4 b3.9 b4.2 b

Dividends Payable

1 m1 m1.7 b1.7 b1.7 b1.8 b1.8 b1.9 b2 b

Current Liabilities

20.4 b24.8 b21.9 b19.9 b20.2 b24.1 b27.8 b34.8 b28.7 b32.1 b24.9 b27.2 b27.4 b32.2 b

Long-term debt

31.8 b27.6 b32.3 b31.7 b29.4 b26.7 b29.1 b30.4 b27.8 b30.5 b31.8 b28.9 b

Total Debt

31.8 b27.6 b32.3 b31.7 b29.4 b26.7 b29.1 b30.4 b27.8 b30.5 b31.8 b28.9 b

Total Liabilities

97.2 b93.7 b95.7 b93.1 b93.1 b93.7 b104 b115 b99.6 b108 b110 b110 b94.1 b94.9 b

Common Stock

452 m454 m454 m455 m458 m458 m459 m461 m460 m461 m463 m463 m465 m465 m

Preferred Stock

35 m32 m31 m30 m28 m28 m27 m25 m26 m25 m23 m23 m21 m20 m

Additional Paid-in Capital

76.8 b77.8 b78.2 b78.5 b80 b80.4 b80.8 b82.5 b81.4 b82.1 b83.1 b83.4 b84.6 b84.9 b

Retained Earnings

70.4 b72 b71.6 b74.3 b74.5 b73.6 b74 b72.8 b75 b73.4 b74.8 b74.1 b90 b89.9 b

Total Equity

78.4 b78.1 b77 b78.3 b67.6 b67.2 b67.1 b63.6 b63.3 b63.1 b58.7 b58.7 b70.5 b70.1 b

Financial Leverage

2.2 x2.2 x2.2 x2.2 x2.4 x2.4 x2.5 x2.8 x2.6 x2.7 x2.9 x2.9 x2.3 x2.4 x

Pfizer Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

22.1 b9.2 b

Accounts Receivable

940 m148 m21 m(134 m)

Inventories

(538 m)175 m(199 m)365 m

Accounts Payable

382 m297 m254 m871 m

Cash From Operating Activities

17.8 b16.9 b14.5 b15.9 b

Purchases of PP&E

(1.2 b)(1.2 b)(1.4 b)(1.8 b)

Cash From Investing Activities

(10.6 b)(5.7 b)(3 b)(7.8 b)

Short-term Borrowings

(1.2 b)(8.2 b)

Long-term Borrowings

(4.1 b)(2.1 b)(3 b)(7.7 b)

Dividends Paid

(6.6 b)(6.6 b)(6.9 b)(7.3 b)

Cash From Financing Activities

(15 b)(10 b)(10.2 b)(8.9 b)

Interest Paid

1.7 b1.6 b1.3 b1.5 b

Income Taxes Paid

2.9 b2.1 b2.4 b2.5 b

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2017Q1, 2019Q2, 2019

Net Income

2.6 b2.3 b2.9 b2.7 b2.4 b3.6 b7.4 b

Depreciation and Amortization

3.1 b1.6 b3.1 b

Cash From Operating Activities

4.8 b2 b5.8 b

Purchases of PP&E

(806 m)(386 m)(810 m)

Cash From Investing Activities

3 b9.7 b8.2 b

Long-term Borrowings

(4.5 b)(355 m)(3.1 b)

Dividends Paid

(3.9 b)(2 b)(4 b)

Cash From Financing Activities

(7.9 b)(10.7 b)(12.6 b)

Interest Paid

881 m259 m724 m

Income Taxes Paid

1.1 b257 m1.2 b

Pfizer Ratios

USDY, 2018

EV/CFO

46.1 x

Financial Leverage

2.4 x
Report incorrect company information

Pfizer Operating Metrics

Pfizer's Properties was reported to be 501 in FY, 2017.
FY, 2014FY, 2015FY, 2016FY, 2017

Active Clinical Studies

448 338

Phase III Trials Products

22 30 34 29

Discovery Projects

91 90 96 87

Countries

125 125

Manufacturing Sites

55 64 63 58

Properties

513 595 567 501

Total Units Delivered

74 b

Vaccines Delivered

135 m
Report incorrect company information